CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1 enrolled
Drug / intervention
Methotrexate +4 moredrug
Likely dose
Methotrexate 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03797872
NCT03797872Phase 4Completed
CompareCT.gov

Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study

University of Oxford·interventional·Posted Jan 9, 2019·Updated May 10, 2021

In Brief

A Phase 4 clinical trial evaluating Methotrexate, Sulfasalazine, and 3 other interventions for Psoriatic Arthritis. Completed, enrolled 1 participant across 1 site.

Detailed Summary

POISE is a two arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests less aggressive early therapy in patients newly diagnosed with low impact oligoarticular PsA. Arm 1 will receive standard step up therapy in the cohort and act as the control group. Arm 2 will receive local steroid injections to active joints and will be able to use non-steroidal anti-inflammatory drugs (NSAIDs) only

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesUnited Kingdom
CollaboratorsNational Institute for Health Research, United Kingdom

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJan 9, 2019
Enrollment StartApr 17, 2019
Primary CompletionJul 16, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.5 years ago

Interventions

Methotrexatedrug

Methotrexate up to 25mg/week as tolerated po or sc

Sulfasalazinedrug

Sulfasalazine up to 3g daily po

Leflunomidedrug

Leflunomide 10-20mg daily po

Methylprednisolonedrug

For IA or IM injection 20-120mg

Triamcinolonedrug

For IA or IM injection 20-120mg